Home Cart Sign in  
Chemical Structure| 914306-50-6 Chemical Structure| 914306-50-6

Structure of 914306-50-6

Chemical Structure| 914306-50-6
Product Citations

Alternative Products

Product Details of [ 914306-50-6 ]

CAS No. :914306-50-6
Formula : C21H24N2
M.W : 304.43
SMILES Code : CC(C1=C(N2C=CN=C2C3=CC=CC=C3)C(C(C)C)=CC=C1)C
MDL No. :MFCD27923076
InChI Key :DGCQHTACQZUATF-UHFFFAOYSA-N
Pubchem ID :58037491

Safety of [ 914306-50-6 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 914306-50-6 ] Show Less

Physicochemical Properties

Num. heavy atoms 23
Num. arom. heavy atoms 17
Fraction Csp3 0.29
Num. rotatable bonds 4
Num. H-bond acceptors 1.0
Num. H-bond donors 0.0
Molar Refractivity 98.16
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

17.82 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

3.44
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

5.59
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

5.79
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

4.44
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

5.18
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

4.89

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-5.53
Solubility 0.000894 mg/ml ; 0.00000294 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Moderately soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-5.73
Solubility 0.000572 mg/ml ; 0.00000188 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Moderately soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-7.08
Solubility 0.0000255 mg/ml ; 0.0000000838 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Poorly soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

No
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

Yes
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

Yes
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

Yes
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

Yes
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

Yes
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-4.19 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

1.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

2.72

Application In Synthesis of [ 914306-50-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 914306-50-6 ]

[ 914306-50-6 ] Synthesis Path-Upstream   1~4

  • 1
  • [ 591-50-4 ]
  • [ 914306-50-6 ]
YieldReaction ConditionsOperation in experiment
78% With tetrakis(triphenylphosphine) palladium(0) In toluene at 120℃; for 16 h; Inert atmosphere In the same procedure as in Synthesis Example 2, the compound 2 was prepared from a solution containing the compound 1 (28.5 g, 125 mmol), tetrahydrofuran (125ml), the n-BuLi-hexane solution (74.9 ml, mole number of n-BuLi in the solution: 125 mmol, molarity (mole number of n-BuLi/solution amount): 1.67M) and zinc chloride (28.4 g, 208 mmol) dissolved in tetrahydrofuran (208 ml). After preparing the compound 2, the compound 2 was put into a three-necked flask, to which an oil-sealed rotary pump was connected through a solvent trap that is cooled using a solvent of dry ice/acetone. The three-necked flask was heated to about 40 degrees C under reduced pressure to remove the solvent (310 ml) from the reaction system (the solvent removal step). A removal amount of the solvent herein is an amount collected by the solvent trap. Subsequently, nitrogen was put into the reaction system to return to the normal pressure. Toluene (104 ml) was put into the reaction system (toluene addition step). Next, iodobenzene (21.3g, 104 mmol) and Pd(PPh3)4 (2.89 g, 2.5 mmol) were added thereto and reacted at 120 degrees C for 16 hours under nitrogen atmosphere. [0151] A relationship of the solvent amounts in the reaction system in Synthesis Example 4 is shown in Table 1. Herein, a relationship between the total volume VA [liter] of tetrahydrofuran (i.e., the ether solvent having at most 5 carbon atoms) and the mole number Nf2 [mol] of iodobenzene is represented below according the same calculation as in Synthesis Example 3 as shown in Table 1. The relationship of the numerical formula (3) was satisfied. Further, a relationship between a volume VB [liter] of toluene (i.e., an aromatic hydrocarbon solvent having 7 carbon atoms) and a mole number Nf2 [mol] of iodobenzene is represented below as shown in Table 1. The relationship of the numerical formula (5) was satisfied. There is a possibility that n-hexane (i.e., an aliphatic hydrocarbon having 6 carbon atoms) is contained in the reaction system even after the solvent removal step in Synthesis Example 4. However, since the volume of n-hexane after the solvent removal step is less than the volume of toluene subsequently added, the relationship of the numerical formula (5) is still satisfied even in consideration of n-hexane. The same applies to Examples 3 and 4 described later. Accordingly, Synthesis Example 4 was conducted under the reaction condition of satisfying the relationships of the numerical formulae (3) and (5). [0152] After the reaction, a small amount of water was added to the sample to deactivate the reaction. The mixture was diluted with dichloromethane (300 ml). An aqueous solution of tetrasodium ethylenediaminetetraacetate dihydrate (129.9 g, 312 mmol) was added to the diluted mixture and stirred in a separating funnel. An aqueous sodium hydroxide was further added thereto to adjust an aqueous phase to pH10 or more. A dichloromethane phase was collected. The aqueous phase was extracted with dichloromethane several times. The extract was dried over anhydrous magnesium sulfate, filtrated and concentrated. The obtained product was refined by silica-gel chromatography (toluene:ethyl acetate=95:5 (volume ratio)) and was further recrystallized in a mixture solvent of hexane/ethyl acetate to obtain a white solid. The compound 4 was identified according to 1H-NMR and FD-MS. Yield: 24.7 g Yield Rate: 78percent
References: [1] Patent: EP2662365, 2013, A1, . Location in patent: Paragraph 0142; 0143; 014; 0150; 0151; 0152; 0173-0176; 0189.
  • 2
  • [ 107-20-0 ]
  • [ 153998-83-5 ]
  • [ 914306-50-6 ]
YieldReaction ConditionsOperation in experiment
100% With sodium hydrogencarbonate In isopropyl alcoholReflux N-(2,6-diisopropylphenyl)benzimidamide (13.60 g, 48.5 mmol), 2-chloroacetaldehyde (12.28 ml, 97 mmol), and sodium hydrogen carbonate (8.15 g, 97 mmol) were combined in 2-propanol (250 ml) and heated at reflux overnight, turning brown. The suspension was cooled to room temperature and filtered through celite, washing with DCM. The filtrate was reduced under vacuum purified by column chromatography, yielding 2 in quantitative yield.
References: [1] Patent: US2018/319830, 2018, A1, . Location in patent: Paragraph 0142.
  • 3
  • [ 24544-04-5 ]
  • [ 914306-50-6 ]
References: [1] European Journal of Organic Chemistry, 2013, # 27, p. 6137 - 6145.
[2] Patent: EP2662365, 2013, A1, .
[3] Patent: US2018/319830, 2018, A1, .
  • 4
  • [ 100-47-0 ]
  • [ 914306-50-6 ]
References: [1] Patent: US2018/319830, 2018, A1, .
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 914306-50-6 ]

Aryls

Chemical Structure| 29914-81-6

A314569 [29914-81-6]

1,3-Bis(1H-benzo[d]imidazol-2-yl)benzene

Similarity: 0.76

Chemical Structure| 670-83-7

A134289 [670-83-7]

2,5-Diphenyl-1H-imidazole

Similarity: 0.73

Chemical Structure| 670-96-2

A132487 [670-96-2]

2-Phenyl-1H-imidazole

Similarity: 0.73

Chemical Structure| 914349-47-6

A105647 [914349-47-6]

(2-(2-Methyl-1H-imidazol-1-yl)phenyl)methanol

Similarity: 0.73

Chemical Structure| 167758-58-9

A735341 [167758-58-9]

(4-(2-Methyl-1H-imidazol-1-yl)phenyl)methanol

Similarity: 0.72